Inventor · disambiguated record
Brian Wong
Also filed as: WONG BRIAN · WONG BRIAN R · WONG BRIAN RUSSELL
42 granted patents·17 pending applications·183 citations·filing 1999–2022
97Inventor score
Files withFIVE PRIME THERAPEUTICS INC18RIGEL PHARMACEUTICALS INC17UNIV ROCKEFELLER7CODEXIS INC4CHOI YONGWON2
Top patents by PatentIndex Score
59 records- 0196US8415365B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2008·Granted Apr 9, 2013·31 cites·20 claims
- 0295US11155615B2Anti-ROR1 antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Oct 26, 2021·13 cites·13 claims
- 0395US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0495US8399472B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2008·Granted Mar 19, 2013·26 cites·4 claims
- 0592US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0691US11198689B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·2 cites·18 claims
- 0791US9365878B2Biocatalytic process for preparing eslicarbazepine and analogs thereofCODEXIS INC·Filed 2015·Granted Jun 14, 2016·3 cites·15 claims
- 0889US8815848B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 26, 2014·8 cites·5 claims
- 0988US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 1088US9963683B2Biocatalytic process for preparing eslicarbazepine and analogs thereofCODEXIS INC·Filed 2017·Granted May 8, 2018·2 cites·20 claims
- 1188US9732073B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2015·Granted Aug 15, 2017·4 cites·17 claims
- 1287US10421752B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Sep 24, 2019·3 cites·14 claims
- 1385US9248190B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Feb 2, 2016·4 cites·7 claims
- 1485US7063960B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereofUNIV ROCKEFELLER·Filed 2002·Granted Jun 20, 2006·7 cites·10 claims
- 1584US9102963B2Biocatalytic process for preparing eslicarbazepine and analogs thereofGOHEL ANUPAM·Filed 2012·Granted Aug 11, 2015·5 cites·11 claims
- 1684US7622442B2Protein belonging to the TNF superfamily involved in signal transduction and methods of use thereofUNIV ROCKEFELLER·Filed 2005·Granted Nov 24, 2009·4 cites·15 claims
- 1781US10221243B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·4 cites·23 claims
- 1881US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1980US11827628B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2021·Granted Nov 28, 2023·0 cites·19 claims
- 2077US11730736B2Anticancer agentsRAPT THERAPEUTICS INC·Filed 2018·Granted Aug 22, 2023·2 cites·15 claims
- 2177US7393927B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereofUNIV ROCKEFELLER·Filed 2005·Granted Jul 1, 2008·1 cites·5 claims
- 2275US7019119B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereofUNIV ROCKEFELLER·Filed 2001·Granted Mar 28, 2006·5 cites·12 claims
- 2374US10982001B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 20, 2021·1 cites·17 claims
- 2473US6890725B2Modulators of B-lymphocyte activation, myosin-1F compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2002·Granted May 10, 2005·2 cites·25 claims
- 2572US9109033B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereofUNIV ROCKEFELLER·Filed 2013·Granted Aug 18, 2015·0 cites·12 claims
- 2671US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 2771US6929923B2Modulators of leukocyte activation, BIC compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Aug 16, 2005·2 cites·20 claims
- 2869US8932838B2Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenolCODEXIS INC·Filed 2014·Granted Jan 13, 2015·0 cites·3 claims
- 2968US10822421B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·0 cites·37 claims
- 3066US9605290B2Biocatalytic process for preparing eslicarbazepine and analogs thereofCODEXIS INC·Filed 2016·Granted Mar 28, 2017·0 cites·20 claims
- 3166US7745196B1Methods and compositions for identifying peptide modulators of cell surface receptorsRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jun 29, 2010·1 cites·35 claims
- 3266US2021277130A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3365US2023192870A1Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3464US2021107986A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3564US2014079699A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)FIVE PRIME THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 3663US2008015337A1Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereofUNIV ROCKEFELLER·Filed 2006·Application pending·0 cites
- 3762US11559583B2Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·0 cites·18 claims
- 3862US8637020B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereofCHOI YONGWON·Filed 2012·Granted Jan 28, 2014·0 cites·4 claims
- 3962US8399628B2Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereofCHOI YONGWON·Filed 2010·Granted Mar 19, 2013·0 cites·7 claims
- 4061US7736846B2Methods of assaying for modulators of the inflammatory process using components of the ubiquitin ligation cascadeRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Jun 15, 2010·3 cites·7 claims
- 4159US11421034B2Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 23, 2022·0 cites·15 claims
- 4258US2013302322A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)FIVE PRIME THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 4355US7723018B2Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascadeRIGEL PHARMACEUTICALS INC·Filed 2003·Granted May 25, 2010·1 cites·13 claims
- 4455US7122332B2Modulators of leukocyte activation, compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2001·Granted Oct 17, 2006·2 cites·8 claims
- 4553US8852900B2Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenolCABIROL FABIEN·Filed 2011·Granted Oct 7, 2014·0 cites·17 claims
- 4651US2018085472A1Combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4749US7371537B2Modulators of B-lymphocyte activation, myosin-1F compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2005·Granted May 13, 2008·0 cites·8 claims
- 4848US2006199218A1Modulators of leukocyte activation, compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4946US2010183620A1Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2BHAWE KAUMUDI·Filed 2009·Application pending·0 cites
- 5043US7045308B2Modulators of leukocyte activation, compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2002·Granted May 16, 2006·0 cites·18 claims
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Brian Wong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →